News | June 17, 2014

AtheroNova Receives Notice of Issuance of Second U.S. Patent

June 17, 2014 — AtheroNova Inc. received a Notice of Issuance for an additional compound for cardiovascular treatments. This patent issuance further exemplifies a plan to develop a broad platform of intellectual property involving atheroma stabilization and reduction, lipid modulation and other metabolic diseases. This issuance continues efforts by the company and its patent counsel in pursuit of numerous patents covering the systemic delivery of naturally occurring bile acids, bile acid synthetics, analogs and conjugates. AtheroNova is a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans.

"This latest patent issuance expands our patent portfolio to now include multiple compounds for addressing atherosclerotic plaque and stands as an important continuation of our goal of being the clear leader in the systemic delivery of bile acids, bile acid synthetics, analogs and conjugates to dramatically enhance cardiovascular and metabolic health," said AtheroNova CEO Thomas W. Gardner. "As our drug development efforts accelerate, the company will continue to pursue additional pending patent applications for systemic delivery of our family of bile acids and bile acid derivatives. The development of our platform is significantly advanced by this achievement."

For more information: www.atheronova.com

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init